Note 14 - Subsequent Events	12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 14. Subsequent Events. Management has evaluated subsequent events through the date of the filing of this Annual Report and management noted the following for disclosure. Summer 2013 Offering Pursuant to a private offering of our common stock at a price of $0.25 per share that commenced June 2013 and subsequent to December 31, 2013 we sold 1,516,663 shares of our common stock to nine accredited investors and received $455,000 gross proceeds from the sales. Clyra Offering On February 1, 2014, Clyra began a private offering of its common stock, at $1,000 per share. On March 14, 2014, Clyra received $50,000 in proceeds from a private offering for its stock, at $1,000 per share. ISAN license agreement In 2012, we executed a joint venture agreement with Peter Holdings Ltd., the principal funding source of the development of the Isan system, whereby we jointly purchased the intellectual property associated with the Isan system. In February 2014 we received a deposit of $100,000 towards a worldwide, exclusive license of the Isan System. We have agreed to provide all technical and engineering specifications, three assembled and operating Isan units, all patent and other intellectual property, and other items related to the Isan operations in Australia and New Zealand. In addition to a $100,000 advanced royalty payment, the licensee has agreed to pay 10% of sales as a royalty, $50,000 minimum per quarter beginning in year 3, a patent maintenance fee of $25,000 annually, paid quarterly in arrears. Final documents are being drafted. Formation of Canadian Subsidiary On January 10, 2014, we formed a wholly-owned Canadian subsidiary, BioLargo Water, Inc., to pursue our efforts to establish a pilot project in association with the University of Alberta. *Issuance of Common Stock in exchange for payment of payables* On March 31, 2014, we paid $92,197 in accounts payable to board members, vendors, and consultants, for bona fide services provided, pursuant to our “accounts payable” conversion plan adopted by our Board of Directors, by the issuance of 226,972 shares of our common stock. *Issuance of Stock* *Optionsin exchange for payment of payables* On March 31, 2014, we issued Options to purchase 235,467 shares of our common stock at an exercise price of $0.43 per share to certain vendors and consultants, in lieu of $67,500 in accrued and unpaid fees, pursuant to our an “accounts payable” conversion plan adopted by our Board of Directors. Issuance of Common Stock in exchange for payment of Note Payables** On March 26, 2014, we paid $275,000 in Note Payables (see Note 9), by the issuance of 1,360,000 shares of our common stock.

Note 14 - Subsequent Events

12 Months Ended

Dec. 31, 2013

Note 14. Subsequent Events.

Management has evaluated subsequent events through the date of the filing of this Annual Report and management noted the following for disclosure.

Summer 2013 Offering

Pursuant to a private offering of our common stock at a price of $0.25 per share that commenced June 2013 and subsequent to December 31, 2013 we sold 1,516,663 shares of our common stock to nine accredited investors and received $455,000 gross proceeds from the sales.

Clyra Offering

On February 1, 2014, Clyra began a private offering of its common stock, at $1,000 per share. On March 14, 2014, Clyra received $50,000 in proceeds from a private offering for its stock, at $1,000 per share.

ISAN license agreement

In 2012, we executed a joint venture agreement with Peter Holdings Ltd., the principal funding source of the development of the Isan system, whereby we jointly purchased the intellectual property associated with the Isan system. In February 2014 we received a deposit of $100,000 towards a worldwide, exclusive license of the Isan System. We have agreed to provide all technical and engineering specifications, three assembled and operating Isan units, all patent and other intellectual property, and other items related to the Isan operations in Australia and New Zealand. In addition to a $100,000 advanced royalty payment, the licensee has agreed to pay 10% of sales as a royalty, $50,000 minimum per quarter beginning in year 3, a patent maintenance fee of $25,000 annually, paid quarterly in arrears. Final documents are being drafted.

Formation of Canadian Subsidiary

On January 10, 2014, we formed a wholly-owned Canadian subsidiary, BioLargo Water, Inc., to pursue our efforts to establish a pilot project in association with the University of Alberta.

Issuance of Common Stock in exchange for payment of payables

On March 31, 2014, we paid $92,197 in accounts payable to board members, vendors, and consultants, for bona fide services provided, pursuant to our “accounts payable” conversion plan adopted by our Board of Directors, by the issuance of 226,972 shares of our common stock.

Issuance of Stock Optionsin exchange for payment of payables

On March 31, 2014, we issued Options to purchase 235,467 shares of our common stock at an exercise price of $0.43 per share to certain vendors and consultants, in lieu of $67,500 in accrued and unpaid fees, pursuant to our an “accounts payable” conversion plan adopted by our Board of Directors.

Issuance of Common Stock in exchange for payment of Note Payables

On March 26, 2014, we paid $275,000 in Note Payables (see Note 9), by the issuance of 1,360,000 shares of our common stock.